These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 12504620)

  • 1. Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study.
    Chan YM; Ng TY; Ngan HY; Wong LC
    Gynecol Oncol; 2003 Jan; 88(1):9-16. PubMed ID: 12504620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
    Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
    Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness.
    da Costa Miranda V; de Souza Fêde ÂB; Dos Anjos CH; da Silva JR; Sanchez FB; da Silva Bessa LR; de Paula Carvalho J; Filho EA; de Freitas D; Del Pilar Estevez Diz M
    Gynecol Oncol; 2014 Feb; 132(2):287-91. PubMed ID: 24333355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
    Bian C; Yao K; Li L; Yi T; Zhao X
    Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
    Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
    J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma.
    Kuhn W; Rutke S; Späthe K; Schmalfeldt B; Florack G; von Hundelshausen B; Pachyn D; Ulm K; Graeff H
    Cancer; 2001 Nov; 92(10):2585-91. PubMed ID: 11745193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer.
    Mazzeo F; Berlière M; Kerger J; Squifflet J; Duck L; D'Hondt V; Humblet Y; Donnez J; Machiels JP
    Gynecol Oncol; 2003 Jul; 90(1):163-9. PubMed ID: 12821358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy.
    Greimel E; Kristensen GB; van der Burg ME; Coronado P; Rustin G; del Rio AS; Reed NS; Nordal RR; Coens C; Vergote I;
    Gynecol Oncol; 2013 Nov; 131(2):437-44. PubMed ID: 23994107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morbidity of surgery after neoadjuvant chemotherapy including bevacizumab for advanced ovarian cancer.
    Chéreau E; Lambaudie E; Houvenaeghel G
    Int J Gynecol Cancer; 2013 Sep; 23(7):1326-30. PubMed ID: 23835506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of advanced ovarian cancer in South West Wales - a comparison between primary debulking surgery and primary chemotherapy treatment strategies in an unselected, consecutive patient cohort.
    Drews F; Bertelli G; Lutchman-Singh K
    Cancer Epidemiol; 2017 Aug; 49():85-91. PubMed ID: 28599137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.
    Fagotti A; Ferrandina G; Vizzielli G; Fanfani F; Gallotta V; Chiantera V; Costantini B; Margariti PA; Gueli Alletti S; Cosentino F; Tortorella L; Scambia G
    Eur J Cancer; 2016 May; 59():22-33. PubMed ID: 26998845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neo-adjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer treatment--a retrospective study].
    Tkácová M; Vertaková-Krakovská B; Belohorská B; Miskovská V; Helpianska L; Ondrus D; Ondrusová M; Spánik S; Svec J
    Klin Onkol; 2009; 22(6):273-7. PubMed ID: 20099745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy.
    Favero G; Macerox N; Pfiffer T; Köhler C; da Costa Miranda V; Estevez Diz Mdel P; Fukushima JT; Baracat EC; Carvalho JP
    Oncology; 2015; 89(3):159-66. PubMed ID: 25968072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemotherapy is associated with prolonged primary treatment intervals in patients with advanced epithelial ovarian cancer.
    Milam MR; Tao X; Coleman RL; Harrell R; Bassett R; Dos Reis R; Ramirez PT
    Int J Gynecol Cancer; 2011 Jan; 21(1):66-71. PubMed ID: 21178571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
    Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer.
    Lim MC; Yoo HJ; Song YJ; Seo SS; Kang S; Kim SH; Yoo CW; Park SY
    J Gynecol Oncol; 2017 Jul; 28(4):e48. PubMed ID: 28541636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
    Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
    Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery.
    Lee SJ; Kim BG; Lee JW; Park CS; Lee JH; Bae DS
    J Obstet Gynaecol Res; 2006 Feb; 32(1):99-106. PubMed ID: 16445534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective analysis of neoadjuvant platinum-based chemotherapy versus up-front surgery in advanced ovarian cancer.
    Steed H; Oza AM; Murphy J; Laframboise S; Lockwood G; DE Petrillo D; Sturgeon J; Rosen B
    Int J Gynecol Cancer; 2006; 16 Suppl 1():47-53. PubMed ID: 16515567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life.
    Brotto L; Brundage M; Hoskins P; Vergote I; Cervantes A; Casado HA; Poveda A; Eisenhauer E; Tu D; ; ;
    Support Care Cancer; 2016 Mar; 24(3):1241-9. PubMed ID: 26304156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.